Pharmaceuticals

Gilead Sciences Exploited Monopoly Right to Set $1,000 for One Pill of Hepatitis C Drug

Gilead Sciences Exploited Monopoly Right to Set $1,000 for One Pill of Hepatitis

Is it right for pharmaceutical companies to charge patients too high for life saving drugs that they innovate and eventually bring in the market after getting the approval? As per a report about earnings of Gilead Sciences, the company has earned $6 billion in profits within six months from the sales of the hepatitis C drug, Sovaldi.

Company: 

AstraZeneca, Roche and Qiagen to Collaborate for Cancer Diagnostic

AstraZeneca, Roche and Qiagen to Collaborate for Cancer Diagnostic

AstraZeneca has signed up an agreement of collaboration with Roche AG and Qiagen for cancer diagnostic technology using genomic data from plasma samples. The companies will share technology and research expertise to develop new blood test.

Qiagen's EGFR test has been approved by FDA and the new test will be using EGFR as base technology. The companies will work together to develop two diagnostic blood tests. The test will indicate the benefits lung cancer patients can derive from the drugs.

Location: 

FDA Approves Extended Use of Lymphoseek

FDA Approves Extended Use of Lymphoseek

Today, the U. S. Food and Drug Administration has given permission for the extended use of Lymphoseek (technetium 99m tilmanocept) Injection. It is a radioactive diagnostic imaging agent being used by doctors to determine the level at which a type of cancer has spread in the body's head and neck region. It is marketed by Navidea Biopharmaceuticals, Inc. based in Dublin, Ohio.

In 2013, Lymphoseek was approved to help doctors identify lymph nodes in proximity with a primary tumor in patients with breast cancer.

Location: 
Company: 

Amgen’s Brodalumab: Potential Treatment against Psoriatic Arthritis

Amgen’s Brodalumab: Potential Treatment against Psoriatic Arthritis

A study funded by Amgen Inc. has developed a drug called brodalumab, which appears to be quite effective in treating psoriatic arthritis. Dr. Philip Mease, a rheumatologist at Swedish Medical Center in Seattle and the lead researcher of the study said that the trials have concluded with positive outcomes.

Psoriatic arthritis is a type of arthritic inflammation that affects as many as 30% of people who have psoriasis and causes scaly red and white patches on the skin. Further, the immune system gets affected, which leads to damage of joints.

Location: 
Company: 

AstraZeneca’s Early-Stage Trials of Experimental Cancer Drug are Encouraging

AstraZeneca’s Early-Stage Trials of Experimental Cancer Drug are Encouraging

At the annual American Society of Clinical Oncology (ASCO) meeting held in Chicago, Britain's AstraZeneca Plc announced about fruitful results from early-stage trials of its experimental cancer drug, MEDI4736.

Sharing the data, the company said they can move into pivotal-stage testing. MEDI4736 is part of closely monitored drugs called as anti-PDL1 therapies. They work by stopping a tumor's ability to escape immune system's defenses.

Location: 
Company: 

Experimental Drug Ramucirumab Improves Chemotherapy Impact on Lung Cancer Patients

Experimental Drug Ramucirumab Improves Chemotherapy Impact on Lung Cancer Patien

An experimental drug, ramucirumab, has been found to extend the life of patients with advanced lung cancer. The drug has been found to increase the survival by more than a month in patients who relapsed after chemotherapy treatment.

In a clinical trial, the impact of Eli Lilly and Co.'s drug Cyramza was tested on 1,200 patients. In April 2014, FDA approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression.

Location: 
Company: 

First Generic Version of Celebrax Approved by FDA

First Generic Version of Celebrax Approved by FDA

The U.S. FDA has approved the generic version of painkiller Celebrex (celecoxib) capsules. The cox-2 inhibitor has been a blockbuster drug for treatment of rheumatoid arthritis, osteoarthritis and other painful conditions.

FDA granted approval to Teva Pharmaceuticals for generic version of celecoxib capsules. The capsules will be available in 50mg, 100mg, 200mg and 400mg dosage. The use of non-steroidal anti-inflammatory drugs (NSAID) has increased in the recent years.

Location: 
Laboratories: 

Sanofi Could Seek Regulatory Approval for Cialis OTC Status

Sanofi Could Seek Regulatory Approval for Cialis OTC in United States

Sanofi and Eli Lilly will work together to get regulatory approval for Cialis (tadalafil) from prescription drug to over the counter. The drug widely prescribed for erectile dysfunction was first approved in year 2002 by the European Medicines Agency.

Cialis accounted for $2.2 billion in sales last year in the US market. Cialis patents could expire in year 2017. The pharmaceutical majors are expecting higher sales if the US FDA approves the drug for Over the counter status.

Location: 
Company: 

US Health Insurer AHIP Considers Gilead’s Solvadi Overpriced

US Health Insurer AHIP Considers Gilead’s Solvadi Overpriced

US Health insurance group America's Health Insurance Plans has condemned the high price of hepatitis C treatment developed by Gilead Sciences Inc. The treatment has recently faced criticism from lawmakers and individual payers.

The hepatitis treatment Solvadi costs nearly $84,000 for complete course. AHIP statement said that Solvadi has shown very good results but the high cost of treatment cannot be justified by the company.

Location: 
Company: 

Intermune’s Nintedanib Found Effective in Fatal Lung Disease

Intermune’s Nintedanib Found Effective in Fatal Lung Disease

Intermune Inc.’s pirfenidone and nintedanib have been found helpful in cases of a fatal lung disease that generally causes death in three to five years. Two separate studies have found the cancer treatment drug having a positive impact in reducing the progression of idiopathic pulmonary fibrosis.

Location: 
Laboratories: 
Company: 

Pages

Popular Stories

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More

Tesla announces risky new approach to customer service

During the past few years, Tesla was slammed by a... Read More

Facebook downranks video clickbait & fake play buttons

Facebook, the world’s most-popular social-... Read More